2-Year Trajectory Analysis Shows Significant Benefit of BIS | ImpediMed
We use cookies to make your visit to our website as pleasant as possible. If you continue to use the website, you agree to our privacy policy and to the use of cookies. More information about cookies and how ImpediMed uses them is available here.
Accept
Press release - June 7, 2020

2-Year Trajectory Analysis Shows Significant Benefit of BIS

ImpediMed announced publication of a trajectory analysis of the PREVENT study that further demonstrates the clear clinical benefit of BIS.
Read more